Abbvie | Protocol M16-066
Risakizumab-anti-IL23-SC maintenance & OLE
Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065.
Abbvie | Protocol M16-067
Molecule: Risakizumab-anti-IL23-IV Induction
Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy.
Arena | Protocol APD334-210 (pending REB Approval)
Study Title: A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Arena | Protocol APD334-303 (pending REB Approval)
Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)
Study Title:
An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis.
Eli Lily | Protocol I6T-MC-AMBG
Molecule: mirikizumab-anti-IL23- SC maintenance +/- IV rescue dose
Study Title:
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.
Eli Lily | Protocol I6T-MC-AMAP
Long Term extension study for I6T-MC-AMBG and I6T-MC-AMAC
Study Title:
A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.
Protocol APD334-302 (pending REB Approval)
Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis